Endevica Bio

Endevica Bio is a clinical-stage biotech leveraging its expertise in peptide and peptidomimetic chemistry to drug the melanocortin (MC) system, the body's central regulator of metabolic homeostasis. In March 2026, the company spun out its lead metabolic assets into a new entity, Kalohexis, which is advancing a pipeline including an oral dual MC3R/MC4R agonist for obesity (710GO, Phase 1-ready) and a dual antagonist for cancer cachexia (mifomelatide, Phase 2). Endevica's core strategy is to develop potent, selective, and bioavailable therapeutics that offer safer and more durable efficacy compared to existing modalities, particularly in high-need metabolic indications.

Rational design of novel peptidomimetics targeting G-protein coupled receptors (GPCRs), with deep expertise in the melanocortin (MC3R/MC4R) system, focusing on potency, selectivity, and oral bioavailability.

In obesity, competition is dominated by injectable GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) from Novo Nordisk and Eli Lilly. Endevica's 710GO aims to compete via an oral route and a differentiated melanocortin mechanism. In cachexia, there are no approved drugs, placing mifomelatide in a first-to-market race against other investigational catabolism inhibitors and appetite stimulants.